Aytu BioPharma, Inc. (AYTU)
NASDAQ: AYTU · Real-Time Price · USD
2.175
+0.045 (2.11%)
At close: May 22, 2026, 4:00 PM EDT
2.190
+0.015 (0.69%)
After-hours: May 22, 2026, 4:10 PM EDT
Aytu BioPharma Stock Forecast
Stock Price Forecast
According to 3 analysts polled by S&P Global, Aytu BioPharma stock has a consensus rating of "Strong Buy" and an average price target of $9.33. The average 1-year stock price forecast is 328.97% higher than the current stock price, while the lowest is $7.00 (+221.84%) and the highest is $14 (+543.68%).
Price Target: $9.33 (+328.97%)
Analyst Consensus: Strong Buy
* Price targets were last updated on Dec 10, 2025.
Analyst Ratings
The average analyst rating for Aytu BioPharma stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Dec '25 | Jan '26 | Feb '26 | Mar '26 | Apr '26 | May '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 3 | 3 | 3 | 3 | 3 | 3 |
| Buy | 0 | 0 | 0 | 0 | 0 | 0 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 3 | 3 | 3 | 3 | 3 | 3 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Ascendiant Capital | Ascendiant Capital | Strong Buy Maintains $13 → $13 | Strong Buy | Maintains | $13 → $13 | +497.70% | Dec 10, 2025 |
| Maxim Group | Maxim Group | Strong Buy Maintains $9 → $7 | Strong Buy | Maintains | $9 → $7 | +221.84% | Sep 25, 2025 |
| Ascendiant Capital | Ascendiant Capital | Strong Buy Maintains $12 → $13 | Strong Buy | Maintains | $12 → $13 | +474.71% | Sep 25, 2025 |
| Lake Street | Lake Street | Strong Buy Initiates $8 | Strong Buy | Initiates | $8 | +267.82% | Jul 1, 2025 |
| Ascendiant Capital | Ascendiant Capital | Strong Buy Initiates $12 | Strong Buy | Initiates | $12 | +451.72% | Jun 30, 2025 |
Financial Forecast
Revenue This Year
54.82M
from 66.38M
Decreased by -17.42%
Revenue Next Year
72.04M
from 54.82M
Increased by 31.42%
EPS This Year
-1.81
from -2.16
EPS Next Year
-0.74
from -1.81
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2026 | 2027 | 2028 |
|---|---|---|---|
| High | 57.6M | 75.6M | |
| Avg | 54.8M | 72.0M | |
| Low | 51.9M | 68.5M |
Revenue Growth
| Revenue Growth | 2026 | 2027 | 2028 |
|---|---|---|---|
| High | -13.3% | 37.9% | |
| Avg | -17.4% | 31.4% | |
| Low | -21.7% | 25.0% |
EPS Forecast
| EPS | 2026 | 2027 | 2028 |
|---|---|---|---|
| High | -1.41 | -0.42 | |
| Avg | -1.81 | -0.74 | |
| Low | -2.17 | -1.04 |
EPS Growth
| EPS Growth | 2026 | 2027 | 2028 |
|---|---|---|---|
| High | - | - | |
| Avg | - | - | |
| Low | - | - |
Sources: Price targets and consensus ratings provided by S&P Global Market Intelligence. Historical ratings and analyst data provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data sources.